This approach, selected due to the superior ability of adenovectors to induce CD8+ T cell responses in humans [36], [43], induced the highest level of sterile protection against malaria (27%) seen to date in a clinical trial using gene-based vaccine platforms [19]. The gene discussed is CD8A; the disease is malaria.